PMVP
NASDAQ:PMVPNASDAQ
1 announcements
Credibility Score100%
PMV Pharmaceuticals Announces Promising Updated Data From the PYNNACLE Phase 2 Pivotal Trial of Rezatapopt Monotherapy in Patients With TP53 Y220C-Mutated Advanced Solid Tumors
Overhypedunclear
Rezatapopt shows a 48% response rate in platinum-resistant ovarian cancer; NDA filing expected Q1 2027.
about 12 hours ago
▼